Month: September 2021

Sep 10 2021

Uncategorized

First and Only Twice-Yearly Treatment for Schizophrenia Receives FDA Approval

by Clinical Editor

No Comments

The one-of-its-kind 6-month paliperidone palmitate treatment for schizophrenia has received FDA approval. The US Food and Drug Administration (FDA) has approved Janssen Pharmaceutical’s long-acting …

Sep 10 2021

Uncategorized

Optimal Antipsychotic Dose for Schizophrenia Relapse Identified

by Clinical Editor

No Comments

A middle-of-the-road dose of an antipsychotic appears to be optimal for relapse prevention in stable schizophrenia, new research suggests.

Sep 09 2021

Uncategorized

Man with schizophrenia admits throwing raw pork bone into mosque

by Clinical Editor

No Comments

A 57-year-old man suffering from from schizophrenia threw a raw pork bone into a mosque in Chinatown in January, a community court heard on Thursday (9 September).

Sep 09 2021

Uncategorized

People with schizophrenia and diabetes at risk for excess mortality, study finds

by Clinical Editor

No Comments

Cardiovascular complications confer the highest relative mortality rate in patients with schizophrenia and diabetes. Hong Kong: Schizophrenia patients with diabetes are at increased risk of …

Sep 09 2021

Uncategorized

USFDA okays Zydus Cadila schizophrenia drug Brexpiprazole

by Clinical Editor

No Comments

Ahmedabad: Drugmaker, Zydus Cadila, today announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Brexpiprazole Tablets in the …

Sep 09 2021

Uncategorized

Zydus Cadila gets USFDA approval for schizophrenia treatment drug

by Clinical Editor

No Comments

Drug firm Zydus Cadila on Thursday said it has received approval from the US health regulator to market Brexpiprazole tablets, used for the treatment of schizophrenia, in the American market.

Sep 09 2021

Uncategorized

Optimal Antipsychotic Dose for Schizophrenia Relapse Identified

by Clinical Editor

No Comments

A middle-of-the-road dose of an antipsychotic appears to be optimal for relapse prevention in stable schizophrenia, new research suggests.

Sep 09 2021

Uncategorized

Schizophrenia study suggests advanced genetic scorecard cannot predict a patient’s fate

by Clinical Editor

No Comments

Researchers found that a tool commonly used in research for evaluating a person’s genetic risk for a disease, called a polygenic risk score, was no better at predicting the outcome...

Sep 08 2021

Uncategorized

Genetic Scorecard for Schizophrenia may Not be as Diagnostic as Anticipated

by Clinical Editor

No Comments

Advanced genetic scorecard may not be able to predict the worsening of a schizophrenic patient’s symptoms as per a study at the Icahn School of Medicine at Mount Sinai, The...

Sep 08 2021

Uncategorized

When Do Schizophrenia Symptoms Start?

by Clinical Editor

No Comments

It’s rare for schizophrenia to appear before 13 or after 40, but it does happen. Here’s when most people develop it and the signs to look out for.